Background-Some evidence suggests that chronic kidney disease is a risk factor for lowerextremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery disease.
disease and stroke (~100-150 per 1,000 patient-years) in this clinical population. 6 Several previous studies have explored the association of mild and moderate stages of chronic kidney disease (CKD) with PAD. [7] [8] [9] [10] [11] [12] [13] [14] However, most of them were cross-sectional [7] [8] [9] [10] and/or investigated either of the two kidney measures to define and stage CKD, estimated glomerular filtration rate (eGFR) or albuminuria, [9] [10] [11] [12] but not both. This kind of limited evidence may have contributed to the lack of inclusion of CKD amongst the risk factors for PAD in the 2016 guidelines on PAD from the American Heart Association (AHA) and the American College of Cardiology (ACC). 15 Therefore, we aimed to quantify the independent and joint associations of eGFR and albuminuria with future risk of PAD using data from 817,084 adults within 21 cohorts in the CKD Prognosis Consortium (CKD-PC). 16 These rich data allowed us to also evaluate prediction improvement of PAD with these CKD measures and explore several different types of PAD such as leg amputation and revascularization.
Methods

Study Selection
Details of the CKD-PC are described elsewhere. 16, 17 Briefly, the CKD-PC is an international consortium aiming to provide evidence that can improve prevention and management of CKD and currently consists of over 70 prospective cohorts including participants from 40 countries/regions with data on eGFR, albuminuria, and clinical outcomes. This current study used data from 9 general population cohorts, 8 cohorts of subjects with at high risk of cardiovascular disease (such as diabetes mellitus), and 4 cohorts exclusively enrolling patients with CKD. These prospective studies had data on incident PAD whereas other cohorts in the CKD-PC did not. This study was approved for use of deidentified data by the Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health, and the need for informed consent was waived.
Cohorts with baseline measurements of eGFR and albuminuria, at least 1000 participants (not applied to cohorts preferentially enrolling individuals with CKD), and at least 50 PAD events were eligible for inclusion. Transfer of individual participant data or standardized analysis of outputs for meta-analysis took place between July 2015 and January 2017, with baseline measurements during 1972-2014.
Variables at Baseline
GFR was primarily estimated by the CKD-EPI creatinine-based equation, 18 since serum creatinine is the most widely used filtration marker in clinical practice. 19 However, as a secondary analysis, we explored eGFR based on the CKD-EPI cystatin-c equation in six studies with relevant data, as this has demonstrated a stronger relationship to clinical outcomes than creatinine-based eGFR. 20 For albuminuria, as recommended by CKD guidelines, 21 we preferred urine albumin-to-creatinine ratio (ACR), but semi-quantitative assessment of proteinuria using a dipstick test was also accepted. 16 We defined the following factors in the AHA/ACC Pooled Cohort Equations 22 as traditional atherosclerotic risk factors: age, gender, race (blacks vs. non-blacks), smoking status (current vs. former/never), systolic blood pressure, antihypertensive drug use, and diabetes (defined as fasting glucose ≥7.0 mmol/L, non-fasting glucose ≥11.1 mmol/L, hemoglobin A1c ≥6.5%, use of antidiabetic drugs, or self-reported diabetes) and levels of total and highdensity lipoprotein cholesterols. A history of other cardiovascular disease (CVD) (coronary heart disease, stroke, and heart failure) was not an exclusion criterion and was treated as a covariate in our study. We took this approach since risk factor profiles are not necessarily the same between PAD and other CVDs. For example, smoking and diabetes are particularly strong predictors of PAD. 1 There are also a few unique aspects for PAD evaluation and monitoring (e.g., ankle brachial index and foot examination). 2, 23 Indeed, a previous risk prediction tool for new development of intermittent claudication from the Framingham Heart Study incorporates a history of coronary heart disease as a predictor. 24 
PAD outcomes
Given heterogeneous literature regarding how to define incident PAD, 11, 12, [24] [25] [26] we investigated the following definitions of PAD: 1. Study-specific PAD (comprehensively defined in each study based on ICD codes or self-report of PAD diagnosis, leg revascularization, leg amputation, intermittent claudication, or repeated ankle-brachial index as available); 2. PAD-related hospitalizations (ICD-9 codes 440. 
Statistical analyses
Analyses were restricted to subjects aged 18 years or older without a history of PAD at baseline. We excluded any subject with missing values for eGFR, albuminuria, or traditional risk factors at baseline. 18 However, we included a few studies that systematically lacked data on some traditional risk factors (details about one or a few missing variables in some cohorts can be found in appendix pp 6-7). All estimates were obtained within each cohort first and then meta-analyzed by a fixed-effect model, with the number of events in each cohort as weights, to have consistent weights between the analysis of risk relationship and risk prediction. 18, 27 Meta-analyses were performed for analyses with estimates from ≥3 cohorts.
Using Cox proportional hazards models, we first quantified the associations of eGFR and albuminuria with PAD outcomes in the general population and high-risk cohorts after adjusting for each other and traditional risk factors. eGFR and ACR were modeled by linear splines with knots at 30, 45, 60, 75, and 90 ml/min/1.73m 2 and 10, 30, and 300 mg/g, respectively. eGFR 95 ml/min/1.73m 2 and ACR 5 mg/g were set as reference. 18 ACR was log-transformed, as were all continuous traditional risk factors. 22, 28 We used Zellner's seemingly unrelated regression 29 to evaluate whether the associations of eGFR and ACR with different definitions of PAD were significantly different or not. We also quantified PAD risk by cross-categories of eGFR and albuminuria in the context of the new international CKD staging system. 21 For this analysis of cross-categories of CKD measures, as previously done, 28, 30 we combined ACR <10, 10-29, 30-299, and ≥300 mg/g and dipstick proteinuria, negative (reference), ± (trace), 1+, and ≥2+, respectively. The same categories of dipstick proteinuria was used when general population and high risk cohorts with data on dipstick were explored in other analyses.
Subsequently, we conducted subgroup analyses by age, sex, race, and history of diabetes, hypertension (defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or use of antihypertensive medications), use of statins, and CVDs. Interaction was tested using meta-regression for average coefficients for spline terms weighted on the number of events in each study (for eGFR, only spine terms <90 ml/min/1.73m 2 were taken into account). We also separately analyzed the subpopulation with CKD including participants with low eGFR <60 ml/min/1.73m 2 or high albuminuria (ACR ≥30 mg/g or dipstick proteinuria ≥1+) 17 from the general population and high-risk cohorts and all participants in the four CKD cohorts. For the analysis of the CKD population, eGFR 50 ml/min/1.73m 2 and ACR 100 mg/g were set as reference, and dipstick proteinuria was categorized into negative/trace (reference), 1+, 2+, and ≥3+, as done previously. 31 Next, we estimated the difference in Harrell's c-statistics, 32 a parameter of risk discrimination accounting for censoring, between prediction models that included or excluded kidney measures (eGFR, albuminuria, or both). To mitigate the methodological advantage for kidney measures having several spline terms, in these prediction analyses, eGFR was modeled with two linear terms with a knot at 60 ml/min/1.73m 2 , as previously done. 18 All models showed good calibration according to visual evaluation of predicted vs. observed risk in the vast majority of cohorts. 33 The assessment of heterogeneity was based on the I 2 statistic and the χ 2 test. Random-effects meta-regression analysis was performed to explore sources of heterogeneity when heterogeneity was high (I 2 statistic >75% 34 ). All analyses were performed with Stata/MP 13 (www.stata.com), and a P-value <0.05 was considered statistically significant.
Role of the funding source
The funders had no role in the study design, data collection, analysis, data interpretation, or writing of the report. KM had full access to all analyses and all authors had final responsibility for the decision to submit for publication, informed by discussions with collaborators.
Results
Study Characteristics
A total of 817,084 individuals free of PAD history, with mean age of 54 (SD 12) years, were followed for a median of 7.4 years (Table 1) . Overall, 33% were diabetic and 9% had history of CVDs. The prevalence of eGFR <60 ml/min/1.73m 2 and high albuminuria were 17% and 5% in general population cohorts, 14% and 20% in high-risk cohorts, and 84% and 66% in CKD cohorts, respectively. During follow-up, 18,261 incident cases of PAD based on studyspecific definitions were reported across all cohorts, 8,014 cases of PAD-related hospitalizations from 8 cohorts, 2,549 cases of leg revascularization from 10 cohorts, and 1,754 cases of leg amputation from 7 cohorts.
Independent Associations of eGFR and Albuminuria with Incident PAD Outcomes
The adjusted risk of incident PAD was largely constant above eGFR 60 ml/min/1.73m 2 and steadily increased below eGFR 60 ml/min/1.73m 2 , with a similar risk gradient across the four definitions of PAD ( Figure 1A-1D ). Compared to eGFR 95 ml/min/1.73m 2 , the hazard ratio (HR) of incident study-specific PAD was 1.22 (95% CI, 1.14-1.30) at eGFR 45 ml/min/1.73m 2 , 1.68 (1.52-1.86) at eGFR 30 ml/min/1.73m 2 , and 2.06 (1.70-2.48) at eGFR 15 ml/min/1.73m 2 ( Figure 1A ). The risk gradient was slightly steeper for eGFR based on cystatin than when based on serum creatinine below <90 ml/min/1.73m 2 (appendix p 11), although we were able to only meta-analyze study-specific PAD due to limited availability of cystatin C.
The associations of ACR with PAD outcomes were generally linear on the log-log scale ( Figure 1E -1H), with significantly increased risk even within the range below the current clinical threshold of abnormality (<30 mg/g). Compared to ACR 5 mg/g, the HR of incident study-specific PAD was 1.10 (95% CI, 1.06-1.14) at ACR 10 mg/g, 1.50 (1.41-1.59) at ACR 30 mg/g, and 2.28 (2.12-2.44) at ACR 300 mg/g ( Figure 1E ). The risk relationship appeared largely similar for study-specific PAD, PAD-related hospitalizations ( Figure 1F ), and leg revascularization ( Figure 1G ) but was steepest for leg amputation ( Figure 1H ). For example, the adjusted HR at ACR 300 mg/g vs. 5 mg/g was 3.68 (95% CI 3.00-4.52) for leg amputation and ~2.5 for the other three outcomes. Moreover, the adjusted HR of leg amputation for log-ACR as a linear term was significantly greater than that of study-specific PAD (p <0.001 by the seemingly unrelated regressions).
Although qualitatively consistent associations were seen in most cohorts, we observed high heterogeneity (I 2 statistic >75%) for HR at eGFR 45 vs. 95 ml/min/1.73m 2 for studyspecific PAD and PAD-related hospitalization (appendix p 12). However, in the metaregression analyses, none of the covariates appeared to explain the difference in HRs across studies (appendix p 27). HR at ACR 30 vs. 5 mg/g did not demonstrate high heterogeneity in any PAD outcomes (appendix p 13). Regarding subgroups, although statistically significant interactions were observed in some combinations of PAD definitions and subgroups (appendix pp [14] [15] [16] [17] [18] [19] [20] , CKD measures were generally associated with increased risk of incident PAD in every subgroup tested. Similar patterns were seen when we analyzed CKD population (appendix p 21).
Joint Associations of eGFR and Albuminuria with Incident PAD Outcomes
We confirmed multiplicative contributions of eGFR and albuminuria to increased PAD risk by modeling their cross-categories in the general/high-risk cohorts including ones with dipstick proteinuria (Figure 2 ). Regardless of PAD definition, the highest risk was observed in the category of severely reduced eGFR <30 ml/min/1.73m 2 plus severely elevated ACR ≥300 mg/g, with HRs of ~6 to 11 compared to the reference category of eGFR ≥90 ml/min/ 1.73m 2 plus ACR <10 mg/g or negative dipstick proteinuria. The categories with mild to moderate abnormality of both eGFR (30-59 ml/min/1.73m 2 ) and ACR (30-299 mg/g) showed 2.1-4.4 times higher risk of PAD outcomes. Lower eGFR and higher ACR were associated with increased risk of PAD even when the other CKD measure was normal (e.g., eGFR 30-59 ml/min/1.73m 2 showed a HR of 1.2-2.4 even when ACR <10 mg/g; and ACR 30-299 mg/g showed a HR of 1.8-2.2 even when eGFR ≥90 ml/min/1.73m 2 ). Generally similar patterns were found when we analyzed CKD population (appendix p 22).
Improvement in Risk Prediction of PAD with Kidney Measures
C-statistics based on traditional risk factors ranged from 0.750 to 0.772 across the four PAD outcomes in the general and high-risk cohorts with ACR data (Figure 3 ). The addition of CKD measures significantly improved PAD risk discrimination beyond traditional risk factors. For all PAD outcomes, the improvement in risk was more evident with ACR than with eGFR (e.g., Δc-statistic: 0.018 [95% CI, 0.015-0.020] vs. 0.010 [0.008-0.011] for study-specific PAD). The improvement was particularly evident for leg amputation when adding ACR, with Δc-statistic 0.058 (95% CI 0.045-0.070). We saw some incremental improvements in c-statistics when eGFR and ACR were added simultaneously. The greater risk improvement with ACR over eGFR was also seen when cystatin C was taken as the filtration marker rather than serum creatinine (appendix p 23).
To compare the contributions of the kidney measures and traditional risk factors to PAD risk, we added each of them in turn to demographic predictors (age, gender, and race) ( Figure 4 ). Of the traditional risk factors, diabetes and a history of other CVDs were consistently the strongest predictors. Of note, ACR consistently improved the risk prediction more than these two potent predictors regardless of PAD outcomes. The contribution of eGFR to risk prediction of PAD was similar to or slightly greater than traditional risk factors other than diabetes and history of CVD. The risk discrimination improvement of PAD was confirmed with dipstick but not as much as ACR data (appendix pp [24] [25] . When we investigated CKD population, the pattern for the contributions of eGFR, ACR, and traditional risk factors to PAD risk prediction was largely similar (appendix p 26), with ACR as one of the most potent predictors.
Discussion
This international collaborative meta-analysis of individual level data in ~0.8 million individuals free of PAD at baseline demonstrates that both eGFR and ACR were independently associated with future risk of PAD. Even mild to moderate CKD conferred 1.5 to 4 times higher risk of PAD beyond traditional risk factors. For ACR, we observed risk gradient even within the range currently considered normal or mildly elevated (i.e., <30 mg/g). 21 The associations were largely consistent across different cohorts as well as key demographic and clinical subgroups such as those with vs. without diabetes or hypertension. Reflecting their strong associations, both kidney measures improved the prediction of PAD risk beyond traditional risk factors, with more evident improvements with ACR than with eGFR. It is noteworthy that the contribution of these kidney measures (particularly ACR) to PAD risk prediction was greater than or similar to any modifiable traditional risk factors including diabetes and history of CVDs. Of interest, ACR substantially improved the prediction of leg amputation.
Although most previous studies have not analyzed the CKD-PAD association longitudinally with both eGFR and albuminuria, 7-12 two previous investigations by Bello et al. 13 and Garimella et al. 14 have done so. However, the former included individuals with a history of PAD at baseline and used a wide definition of PAD including atherosclerotic events beyond lower-extremity such as aortic aneurysm and renal artery stenosis. 13 The latter used decline in ABI below ≤0.9 as an outcome variable. 14 Therefore, our study expanded to clinical lower-extremity PAD including leg amputation. Other unique aspects of our study include meta-analysis of individual level data (mostly unpublished data), a collaborative investigation of international cohorts, extensive subgroup analyses, and a sophisticated evaluation of c-statistics.
Overall, our results suggest important pathophysiological contributions of CKD to the development of PAD above and beyond traditional risk factors, although the current study is not designed to elucidate mechanisms. Nonetheless, it is worth emphasizing that both CKD measures contributed to PAD risk even among those without diabetes or hypertension, suggesting that eGFR and albuminuria are not merely end-organ damage markers of these traditional atherosclerotic risk factors. Indeed, there are several plausible mechanisms linking CKD to PAD, which include, but are not limited to, activation of renin-angiotensin system, oxidative stress, inflammation, hypercoagulability, abnormal calcium-phosphate metabolism, elevation of lipoprotein(a), and accumulation of uremic toxins. 35 In addition, albuminuria is linked to endothelial dysfunction and/or microvascular damage. 36 This aspect may explain the particularly strong contribution of albuminuria to the risk of leg amputation. The development of critical limb ischemia as a severe form of PAD has been suggested to be due to a compromised microcirculation resulting in an impaired collateral formation and wound healing. 37, 38 It is noteworthy that higher ACR was associated with incident PAD even within the range currently considered normal or mildly elevated (i.e., <30 mg/g). 21 This pattern was seen also for other cardiovascular outcomes (e.g., cardiovascular mortality, coronary heart disease, and heart failure), 18, 28 making some experts propose a lower threshold of "elevated" albuminuria. 39 Decisions on thresholds for albuminuria should involve comprehensive consideration about the distribution of a relevant biomarker in the target population, the need of age-or sex-specific thresholds, contribution to clinical outcomes, and cost-effectiveness of clinical management triggered by identifying "abnormal" values of that biomarker. 28, [40] [41] [42] In terms of distribution, 19.1% of participants in our general population cohorts had ACR <10 mg/g. Nonetheless, it seems worth paying attention to any future evidence informing this important issue, particularly cost-effectiveness of any interventions targeting mildly elevated ACR below 30 mg/g. The strong association between CKD and PAD may not be surprising since CKD is sometimes regarded as an equivalent atherosclerotic disease in terms of prognosis, 43 but our study has clinical implications since there are unique aspects to the diagnosis and management of PAD. Although the AHA/ACC 2016 Guideline on PAD does not specify CKD as a risk factor of PAD, 15 our results indicate that individuals with CKD even at mild to moderate stages may warrant clinical attention to leg signs and symptoms of PAD. Annual foot care is currently recommended in patients with diabetes, 23 but adherence to this recommendation is only ~30%. 44 Thus, as the first step to improve this low adherence, those with both diabetes and CKD (particularly when albuminuria is present) may be a reasonable target to strongly encourage regular foot care. From the practical point of view, it is important that the assessment of kidney function and albuminuria is already recommended in patients with diabetes as well as in those with hypertension. 21, 23, 45 Thus, in these clinical populations, the CKD measures should be readily available to classify the risk of PAD. Moreover, a few groups have proposed prediction models for PAD risk for the general population, 24, 33 but none of those take into consideration CKD measures. In this context, it is important that CKD measures improved PAD prediction even among individuals without diabetes or hypertension in our study.
Although this is the most comprehensive study yet conducted for the prospective association of CKD with incident PAD, the results should be interpreted with appropriate caution. As mentioned, the definitions of PAD outcomes varied across cohorts. In addition, some definitions (e.g., clinical diagnosis and hospitalization for PAD included as a part of studyspecific PAD in several studies) might be prone to ascertainment bias, particularly among advanced CKD. Nonetheless, it is important that the results were consistent across different PAD outcomes including a harder outcome of leg amputation. Similarly, the methods used to assess creatinine, albuminuria, and traditional risk factors were not necessarily consistent across cohorts, although we standardized their definitions as much as possible (appendix pp 6-7). Our study population predominantly consisted of whites and blacks, and thus confirmatory investigation is needed for other racial/ethnic groups. Also, as any other observational studies, residual confounding due to unevaluated potential confounders (e.g., physical activity) could have occurred.
In conclusion, even mild to moderate CKD conferred ~1.5-4 times higher risk of incident PAD beyond and above traditional atherosclerotic risk factors. The albuminuria-amputation relationship was remarkably strong. Our results suggest that clinical attention should be paid to the development of leg symptoms and clinical signs of PAD in persons with any stages of CKD.
Panel: Research in context
Evidence before this study Lower-extremity peripheral artery disease (PAD) is an important complication for patients on hemodialysis, and indeed its incident rate is much higher than that for coronary heart disease and stroke in this clinical population. For less severe stages of chronic kidney disease (CKD), several previous studies have explored the risk for PAD, but most of them were cross-sectional and/or investigated either of the two kidney measures to define and stage CKD, estimated glomerular filtration rate (eGFR) or albuminuria, but not both. This kind of limited evidence may have contributed to the lack of inclusion of CKD amongst the risk factors for PAD in the 2016 guidelines on PAD from the American Heart Association and the American College of Cardiology. Matsushita 
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Added value of this study
This individual-level data meta-analysis, with 18,261 incident PAD cases from 0.8 million participants from 21 cohorts, examined the prospective and independent associations of eGFR and albuminuria with future risk of peripheral artery disease (PAD). We observed that both reduced eGFR and albuminuria were independently associated with future risk of PAD. Even mild to moderate CKD conferred 1.5 to 4 times higher risk of PAD beyond traditional risk factors. Accordingly, both kidney measures improved the prediction of PAD risk beyond traditional risk factors, with more evident improvements with albuminuria than with eGFR. Of interest, albuminuria was particularly strongly associated with the risk of leg amputation and substantially improved its risk prediction.
Implications of all the available evidence
Our results indicate that individuals with CKD even at mild to moderate stages may warrant clinical attention to leg signs and symptoms of PAD. Annual foot care is currently recommended in patients with diabetes, but adherence to this recommendation is low. Thus, as the first step to improve this low adherence, those with both diabetes and CKD (particularly when albuminuria is present) may be a reasonable target to strongly encourage regular foot care. From the practical point of view, it is important that the assessment of kidney function and albuminuria is already recommended in patients with diabetes as well as in those with hypertension. Thus, in these clinical populations, the CKD measures should be readily available to classify the risk of PAD. Adjusted hazard ratios and 95% confidence intervals (shaded areas) for each definition of peripheral artery disease according to eGFR (panels A-D) and ACR (panels E-H). The reference value is eGFR 95 mL/min/1.73m 2 and ACR 5 mg/g (diamonds). Adjusted for age, sex, race or ethnic origin, smoking, systolic blood pressure, antihypertensive drugs, diabetes, total and HDL cholesterol concentrations, and albuminuria (ACR or dipstick) or eGFR, as appropriate. Panels A-D included cohorts with dipstick proteinuria, and panels E-H were based on cohorts with ACR data. Categorical analysis of peripheral artery disease outcome definitions with eGFR and ACR in the combined general population and high-risk cohorts. Panels show adjusted hazard ratios derived from categorical analysis of the general population and high-risk cohorts. Dipstick −, ±, 1+, and ≥2+ were combined with ACR categories, as appropriate. Color coding is based on following cutoffs: green indicating <1.5; yellow 1.5 − <2; orange 2−<4; and red ≥4. Bold indicates statistical significance. Difference in C statistics and 95% CIs for each definition of peripheral artery disease after addition of kidney measures to traditional models (age, sex, race, smoking status, systolic blood pressure, antihypertensive drug use, and diabetes, levels of total and high-density lipoprotein cholesterols, and history of cardiovascular disease) in the combined general population and high-risk cohorts. Data are n, n (%), mean (SD), or median (IQR). For definitions of study acronyms and references, see online appendix 3. HDL: high-density lipoprotein, CVD: cardiovascular disease, eGFR: estimated glomerular filtration rate, ACR: urine albumin-to-creatinine ratio, PAD: peripheral artery disease.
